Product/process development, tolling

Equipment—client may not have the equipment required to manufacture a specific product. It may be that available capital and installation time are limited such that they simply can not design, acquire, install and test the process equipment to reach the desired capacity within the available budget and time. If a product is in the early stages of its life cycle, the capital required may be hard to justify. This could be based upon the low initial volume anticipated while developing the market or the need to take advantage of a time-sensitive business opportunity. Tolling can provide a means to safely produce introductoiy, short-term, or small volume products that would otherwise be uneconomic. 

Attached is our businesses Technolog Package Request. This information will be helpful m allowing us to meet your needs and expectations by selecting an appropriate toller. Our department developed this list to identify issues to consider m the tolled manufacturing of your product. Any information that you are able to provide will help us considerably and expedite our evaluation process. We look forward to working with you on this opportunity. 

In this phase of the toller selection process, we assume the long list became a short list and now one or more candidate tollers from the short list will be given an opportunity to prepare a commercial bid. This by no means indicates the short listed tollers are perfect. There may be deficiencies that need to be corrected in concert with the client. With proper effort, one will be successful and be engaged for the toll. Sometimes it is appropriate to decide on a backup toller, as complications can develop that prevent the primary candidate from executing the project as originally planned, due to an incident in their plant, departure of key personnel, or unexpected production demands on the toller. 

It is incumbent upon the toller to develop and follow internal management systems as appropriate to support business needs, production needs, process safety, environmental responsibility, and worker health. The selection process should have considered whether or not satisfactory systems are in place. Nevertheless, the contract or auxiliary documents may be the vehicle used to help ensure that the system reviewed is the system actually used for completing the toll in question. Within the process safety management system, the management of change and training elements are essential subsystems. 

As discussed in Chapter 2, The Toller Selection Process, evaluating the site s safe work practice procedures should have been a part of the review during the toller selection process. Still, new materials may indicate a need to revise or develop special procedures to address unique chemical and physical hazards. New hazards such as vacuum, ciyogenics, ultra-high pressure, or new rotating equipment could be introduced. Medical monitoring requirements or special handling and spill response procedures for the toll s raw materials and products may indicate a need to write or revise safe work practices. 

Toll signaling now appears to be one of the most evolu-tionarily conserved processes known. All the components between Toll and the activation of Dorsal have been largely conserved. There are 8 Drosophila proteins related to Toll plus Toll itself and 10 Toll-related human proteins that control the production of a wide variety of antimicrobial peptides in flies and cytokines in mammals. These molecules provide a rapid, nonspecific defense against infection by a wide array of pathogens. The adaptive immune response mounted by vertebrates, involving antibodies and T cells, is directed against specific pathogens but is slower to develop than the innate, nonspecific response. 

Scale-up, even from laboratory batch to commercial batch operations, is very difficult and can not be totally predicted by tendencies or rules that are obtained as results of systematic variations of assumptions in model equations. As a result, vendors maintain an often extensive test facility, potentially with differently sized equipment (see Section 11.2) to more accurately predict the behavior of the commercial system. Particularly in the more regulated industries, which process materials such as food and pharmaceuticals with high profit margins, a new trend is towards tolling operations (see Sections 11.2 and 14.1) either during the development phase or for the manufacturing of an intermediate or a particular final product during its entire life. 

An important compound with biological activity of clavines is represented by 6 as end product of EA biosynthesis in A. fumigatus. In animal experiments using rats, 6 exhibited vasorelaxant effects on isolated thoracic aortic rings independent of endothelial mediators. Several mechanisms are proposed for the vasorelaxant effect of 6. These results indicate that 6 has potential capacity in vascular protection and may be used as therapeutic dmg against cardiovascular diseases [78]. Treatment of mice with induced liver damage and colitis with 6 showed clear beneficial effects on these diseases [79, 80]. In addition, it has also been demonstrated that 6 exhibits potential relevance as an antiatherosclerotic agent. Inflammation processes like activation of toll-like receptor 4 (TLR 4) and nuclear factor kB (NFkB) have been shown to be responsible in the development... 

---